

**TDMS No.** 95011 - 06  
**Test Type:** CHRONIC  
**Route:** GAVAGE  
**Species/Strain:** MICE/B6C3F1

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)**  
5-(HYDROXYMETHYL)-2-FURFURAL  
**CAS Number:** 67-47-0  
**Pathologist:** TOFT, J. - Blackshear, P.  
F1\_M3

**Date Report Reqsted:** 11/10/2006  
**Time Report Reqsted:** 09:06:29  
**First Dose M/F:** 08/09/01 / 08/08/01  
**Lab:** BAT

**C Number:** C95011B

**Lock Date:** 03/11/2004

**Cage Range:** ALL

**Date Range:** ALL

**Reasons For Removal:** 25021 TSAC 25020 NATD 25019 MSAC  
25018 DACC

**Removal Date Range:** ALL

**Treatment Groups:** Include ALL

TDMS No. 95011 - 06  
Test Type: CHRONIC  
Route: GAVAGE  
Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
5-(HYDROXYMETHYL)-2-FURFURAL  
CAS Number: 67-47-0  
Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
Time Report Requested: 09:06:29  
First Dose M/F: 08/09/01 / 08/08/01  
Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Dosing Accident				2
Moribund Sacrifice	6	9	4	1
Natural Death	4	6	3	31
Survivors				
Natural Death				1
Terminal Sacrifice	40	35	43	14
Animals Examined Microscopically	50	50	50	49
<b>ALIMENTARY SYSTEM</b>				
Gallbladder	(49)	(50)	(49)	(49)
Infiltration Cellular, Mononuclear Cell	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Necrosis		1 (2%)		
Intestine Large, Cecum	(50)	(50)	(50)	(49)
Intestine Large, Colon	(50)	(50)	(50)	(49)
Intestine Small, Duodenum	(50)	(50)	(50)	(49)
Intestine Small, Ileum	(49)	(50)	(50)	(49)
Inflammation, Chronic Active		1 (2%)		
Intestine Small, Jejunum	(50)	(50)	(50)	(49)
Inflammation, Chronic Active		2 (4%)	1 (2%)	
Peyer's Patch, Hyperplasia, Lymphoid		2 (4%)		
Liver	(50)	(50)	(50)	(49)
Basophilic Focus		4 (8%)	5 (10%)	1 (2%)
Clear Cell Focus	26 (52%)	21 (42%)	26 (52%)	1 (2%)
Cyst		1 (2%)		
Eosinophilic Focus	7 (14%)	9 (18%)	16 (32%)	8 (16%)
Hematopoietic Cell Proliferation		2 (4%)		
Infarct	3 (6%)	2 (4%)	1 (2%)	1 (2%)
Infiltration Cellular, Mononuclear Cell	6 (12%)	9 (18%)	6 (12%)	1 (2%)
Inflammation, Granulomatous		1 (2%)		
Inflammation, Chronic Active	37 (74%)	30 (60%)	38 (76%)	19 (39%)
Mineralization	1 (2%)		1 (2%)	2 (4%)
Mixed Cell Focus	5 (10%)	11 (22%)	15 (30%)	3 (6%)
Pigmentation		1 (2%)	1 (2%)	1 (2%)
Thrombosis			1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Bile Duct, Hyperplasia			1 (2%)	
Hepatocyte, Necrosis	2 (4%)	4 (8%)	5 (10%)	1 (2%)
Hepatocyte, Tension Lipidosis	1 (2%)		2 (4%)	1 (2%)
Hepatocyte, Vacuolization Cytoplasmic	31 (62%)	28 (56%)	30 (60%)	10 (20%)
Mesentery	(4)	(4)	(4)	(2)
Pigmentation			1 (25%)	
Artery, Inflammation, Chronic Active			1 (25%)	
Fat, Fibrosis	2 (50%)	2 (50%)	2 (50%)	2 (100%)
Fat, Inflammation, Chronic Active	2 (50%)	3 (75%)	3 (75%)	2 (100%)
Fat, Mineralization	2 (50%)	2 (50%)	3 (75%)	2 (100%)
Fat, Necrosis	2 (50%)	2 (50%)	2 (50%)	2 (100%)
Pancreas	(50)	(50)	(50)	(49)
Acinus, Atrophy	1 (2%)	2 (4%)		
Artery, Inflammation, Chronic Active	2 (4%)	1 (2%)		
Salivary Glands	(50)	(50)	(50)	(49)
Atrophy			1 (2%)	
Mineralization			1 (2%)	
Artery, Mineralization	2 (4%)			
Stomach, Forestomach	(50)	(50)	(50)	(49)
Inflammation, Chronic Active	1 (2%)	5 (10%)	3 (6%)	2 (4%)
Ulcer		1 (2%)	2 (4%)	
Epithelium, Hyperkeratosis		2 (4%)	2 (4%)	4 (8%)
Epithelium, Hyperplasia	1 (2%)	4 (8%)	4 (8%)	4 (8%)
Stomach, Glandular	(50)	(50)	(50)	(49)
Dysplasia		1 (2%)		
Infiltration Cellular, Mast Cell			1 (2%)	
Inflammation, Chronic Active		1 (2%)		
Mineralization		1 (2%)	2 (4%)	
Tooth	(12)	(7)	(4)	(1)
Inflammation, Chronic Active		1 (14%)		
Malformation	10 (83%)	3 (43%)	2 (50%)	1 (100%)
Gingiva, Inflammation, Chronic Active	2 (17%)			

#### CARDIOVASCULAR SYSTEM

Blood Vessel	(3)	(1)	(0)	(1)
Inflammation, Chronic Active	1 (33%)			
Heart	(50)	(49)	(50)	(49)
Cardiomyopathy			2 (4%)	2 (4%)
Inflammation, Chronic Active	1 (2%)			
Mineralization	1 (2%)	1 (2%)	1 (2%)	4 (8%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Thrombosis			1 (2%)	
Artery, Inflammation, Chronic Active	1 (2%)	1 (2%)	3 (6%)	
ENDOCRINE SYSTEM				
Adrenal Cortex	(49)	(50)	(50)	(49)
Accessory Adrenal Cortical Nodule		2 (4%)	1 (2%)	
Degeneration, Fatty	1 (2%)			
Hyperplasia				1 (2%)
Hypertrophy	13 (27%)	20 (40%)	13 (26%)	6 (12%)
Subcapsular, Hyperplasia	45 (92%)	41 (82%)	46 (92%)	41 (84%)
Zona Fasciculata, Hyperplasia		4 (8%)	1 (2%)	
Zona Glomerulosa, Hyperplasia		1 (2%)		
Adrenal Medulla	(49)	(50)	(50)	(49)
Islets, Pancreatic	(50)	(50)	(50)	(49)
Hyperplasia	1 (2%)			
Parathyroid Gland	(41)	(48)	(48)	(37)
Cyst		2 (4%)		1 (3%)
Pituitary Gland	(48)	(50)	(50)	(49)
Pars Distalis, Cyst	6 (13%)	2 (4%)	3 (6%)	2 (4%)
Pars Distalis, Hyperplasia			1 (2%)	
Thyroid Gland	(50)	(50)	(50)	(49)
Inflammation, Chronic Active	1 (2%)	1 (2%)	1 (2%)	1 (2%)
Follicle, Cyst	5 (10%)	2 (4%)	1 (2%)	1 (2%)
Follicle, Degeneration	9 (18%)	13 (26%)	9 (18%)	5 (10%)
Follicular Cell, Hyperplasia	17 (34%)	8 (16%)	13 (26%)	6 (12%)
GENERAL BODY SYSTEM				
None				
GENITAL SYSTEM				
Coagulating Gland	(0)	(2)	(2)	(0)
Atrophy			1 (50%)	
Inflammation, Chronic Active		1 (50%)		
Epididymis	(50)	(50)	(50)	(49)
Atrophy			1 (2%)	
Granuloma Sperm	1 (2%)	1 (2%)		
Mineralization	2 (4%)			

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Preputial Gland	(50)	(50)	(50)	(49)
Infiltration Cellular, Mononuclear Cell			1 (2%)	
Inflammation, Chronic Active	7 (14%)	3 (6%)	2 (4%)	
Bilateral, Duct, Ectasia			1 (2%)	
Duct, Ectasia	10 (20%)	7 (14%)	7 (14%)	7 (14%)
Prostate	(50)	(50)	(50)	(49)
Inflammation, Chronic Active		1 (2%)		
Artery, Inflammation, Chronic Active	1 (2%)	1 (2%)		
Seminal Vesicle	(50)	(50)	(50)	(49)
Atrophy			1 (2%)	
Inflammation, Chronic Active	1 (2%)			
Testes	(50)	(50)	(50)	(49)
Atrophy			1 (2%)	
Mineralization	2 (4%)	2 (4%)	4 (8%)	1 (2%)
Bilateral, Germinal Epithelium, Degeneration			1 (2%)	
Germinal Epithelium, Degeneration			1 (2%)	2 (4%)
HEMATOPOIETIC SYSTEM				
Bone Marrow	(50)	(50)	(50)	(49)
Myeloid Cell, Hyperplasia		1 (2%)		
Lymph Node	(4)	(3)	(4)	(0)
Inguinal, Hyperplasia, Lymphoid	1 (25%)			
Mediastinal, Hyperplasia, Lymphoid	1 (25%)	1 (33%)		
Pancreatic, Hematopoietic Cell Proliferation		1 (33%)		
Lymph Node, Mandibular	(49)	(50)	(49)	(48)
Hyperplasia, Lymphoid	6 (12%)	4 (8%)	7 (14%)	
Lymph Node, Mesenteric	(50)	(49)	(49)	(49)
Hyperplasia, Lymphoid	2 (4%)	3 (6%)	5 (10%)	
Infiltration Cellular, Plasma Cell			1 (2%)	
Spleen	(50)	(50)	(50)	(49)
Hematopoietic Cell Proliferation	11 (22%)	16 (32%)	11 (22%)	2 (4%)
Lymphoid Follicle, Hyperplasia		3 (6%)	4 (8%)	
Thymus	(43)	(47)	(47)	(49)
Atrophy	18 (42%)	23 (49%)	16 (34%)	9 (18%)
Cyst	25 (58%)	19 (40%)	26 (55%)	23 (47%)
Ectopic Parathyroid Gland	2 (5%)	1 (2%)	1 (2%)	

#### INTEGUMENTARY SYSTEM

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Skin	(50)	(50)	(50)	(49)
Inflammation, Chronic Active	2 (4%)	3 (6%)	2 (4%)	
Epidermis, Hyperkeratosis		1 (2%)		
Epidermis, Hyperplasia	2 (4%)	2 (4%)	1 (2%)	
Epidermis, Ulcer	2 (4%)	3 (6%)	1 (2%)	
Subcutaneous Tissue, Inflammation, Chronic Active		1 (2%)		1 (2%)
Subcutaneous Tissue, Mineralization				1 (2%)
Subcutaneous Tissue, Necrosis				1 (2%)
MUSCULOSKELETAL SYSTEM				
Skeletal Muscle	(1)	(4)	(1)	(1)
NERVOUS SYSTEM				
Brain	(50)	(50)	(50)	(49)
Degeneration				3 (6%)
Artery, Inflammation				1 (2%)
Cerebrum, Hippocampus Neuron, Necrosis, Focal			1 (2%)	
RESPIRATORY SYSTEM				
Lung	(50)	(50)	(50)	(49)
Infiltration Cellular, Mononuclear Cell	1 (2%)			
Inflammation, Chronic Active	4 (8%)	2 (4%)	2 (4%)	
Mineralization		1 (2%)	1 (2%)	
Pigmentation			1 (2%)	
Thrombosis				1 (2%)
Alveolar Epithelium, Hyperplasia	3 (6%)	1 (2%)	2 (4%)	7 (14%)
Alveolus, Infiltration Cellular, Histiocyte	3 (6%)	1 (2%)	2 (4%)	
Artery, Mediastinum, Inflammation, Chronic Active		1 (2%)		
Glands, Inflammation, Chronic Active	1 (2%)	1 (2%)		
Nose	(50)	(50)	(50)	(47)
Edema	1 (2%)	2 (4%)		
Inflammation, Chronic Active		6 (12%)	18 (36%)	45 (96%)
Polyp, Inflammatory		1 (2%)		
Glands, Dilatation	16 (32%)	22 (44%)	47 (94%)	45 (96%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE MALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Glands, Hyperplasia	3 (6%)	7 (14%)	45 (90%)	45 (96%)
Glands, Inflammation, Chronic Active	4 (8%)	12 (24%)	34 (68%)	43 (91%)
Nasolacrimal Duct, Inflammation, Suppurative	2 (4%)	1 (2%)		
Olfactory Epithelium, Accumulation, Hyaline Droplet	13 (26%)	17 (34%)	29 (58%)	27 (57%)
Olfactory Epithelium, Degeneration	4 (8%)	2 (4%)	17 (34%)	39 (83%)
Olfactory Epithelium, Hyperplasia			2 (4%)	3 (6%)
Olfactory Epithelium, Metaplasia	1 (2%)	7 (14%)	38 (76%)	43 (91%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	14 (28%)	17 (34%)	23 (46%)	31 (66%)
SPECIAL SENSES SYSTEM				
Eye	(50)	(50)	(50)	(49)
Cornea, Inflammation, Chronic Active	2 (4%)	1 (2%)		
Harderian Gland	(50)	(50)	(50)	(48)
Hyperplasia	4 (8%)	5 (10%)	1 (2%)	1 (2%)
Inflammation, Chronic Active			1 (2%)	
URINARY SYSTEM				
Kidney	(50)	(50)	(50)	(49)
Hydronephrosis				1 (2%)
Infarct	1 (2%)	1 (2%)	3 (6%)	
Metaplasia, Osseous		1 (2%)	3 (6%)	
Mineralization	43 (86%)	43 (86%)	44 (88%)	29 (59%)
Nephropathy	49 (98%)	48 (96%)	46 (92%)	30 (61%)
Artery, Inflammation, Chronic Active	3 (6%)	1 (2%)	3 (6%)	
Renal Tubule, Cyst	20 (40%)	12 (24%)	15 (30%)	
Renal Tubule, Dilatation	1 (2%)			
Renal Tubule, Hyperplasia			1 (2%)	
Renal Tubule, Pigmentation			1 (2%)	
Urinary Bladder	(50)	(50)	(50)	(49)
Mineralization			1 (2%)	1 (2%)

\*\*\* END OF MALE \*\*\*

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
<b>Disposition Summary</b>				
Animals Initially in Study	50	50	50	50
Early Deaths				
Moribund Sacrifice	4	5	8	6
Natural Death	7	2	10	22
Survivors				
Terminal Sacrifice	39	42	32	22
Animals Examined Microscopically	50	49	50	50
<b>ALIMENTARY SYSTEM</b>				
Gallbladder	(50)	(48)	(49)	(48)
Infiltration Cellular, Mononuclear Cell	3 (6%)	2 (4%)		
Intestine Large, Cecum	(50)	(49)	(50)	(50)
Lymphoid Tissue, Hyperplasia	1 (2%)			
Intestine Large, Colon	(50)	(49)	(50)	(50)
Artery, Inflammation, Chronic Active	1 (2%)		1 (2%)	
Intestine Large, Rectum	(50)	(49)	(50)	(50)
Intestine Small, Duodenum	(50)	(49)	(50)	(50)
Intestine Small, Ileum	(50)	(49)	(50)	(49)
Intestine Small, Jejunum	(50)	(49)	(50)	(50)
Peyer's Patch, Hyperplasia, Lymphoid			1 (2%)	
Liver	(50)	(49)	(50)	(50)
Basophilic Focus		6 (12%)	5 (10%)	
Clear Cell Focus	1 (2%)	1 (2%)		
Eosinophilic Focus	6 (12%)	14 (29%)	6 (12%)	3 (6%)
Hematopoietic Cell Proliferation	1 (2%)	2 (4%)	1 (2%)	
Hemorrhage			1 (2%)	
Infiltration Cellular, Mononuclear Cell	32 (64%)	45 (92%)	34 (68%)	27 (54%)
Inflammation, Granulomatous	1 (2%)			
Inflammation, Chronic Active	40 (80%)	45 (92%)	41 (82%)	36 (72%)
Mineralization		1 (2%)	1 (2%)	
Mixed Cell Focus	4 (8%)	5 (10%)	6 (12%)	
Pigmentation			1 (2%)	
Thrombosis			1 (2%)	
Bile Duct, Cyst			1 (2%)	
Hepatocyte, Necrosis	2 (4%)		3 (6%)	1 (2%)
Hepatocyte, Tension Lipidosis	5 (10%)	4 (8%)	2 (4%)	

a - Number of animals examined microscopically at site and number of animals with lesion



TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Hepatocyte, Vacuolization Cytoplasmic	34 (68%)	41 (84%)	34 (68%)	28 (56%)
Mesentery	(12)	(7)	(6)	(1)
Infiltration Cellular, Mononuclear Cell	1 (8%)			
Artery, Inflammation, Chronic Active				1 (100%)
Fat, Fibrosis	9 (75%)	4 (57%)	3 (50%)	
Fat, Inflammation, Chronic Active	6 (50%)	5 (71%)	3 (50%)	
Fat, Metaplasia, Osseous		1 (14%)		
Fat, Mineralization	6 (50%)	3 (43%)	1 (17%)	
Fat, Necrosis	9 (75%)	4 (57%)	3 (50%)	
Pancreas	(49)	(49)	(50)	(50)
Cyst				1 (2%)
Inflammation, Chronic Active				1 (2%)
Acinus, Atrophy		1 (2%)	2 (4%)	
Acinus, Hypertrophy	1 (2%)			
Salivary Glands	(49)	(49)	(49)	(43)
Artery, Inflammation, Chronic Active		1 (2%)	1 (2%)	1 (2%)
Stomach, Forestomach	(50)	(49)	(50)	(50)
Inflammation, Chronic Active		2 (4%)		
Ulcer		1 (2%)		
Epithelium, Hyperkeratosis	2 (4%)	2 (4%)		1 (2%)
Epithelium, Hyperplasia	2 (4%)	2 (4%)	2 (4%)	1 (2%)
Stomach, Glandular	(50)	(49)	(50)	(50)
Mineralization	3 (6%)	1 (2%)	1 (2%)	1 (2%)
Tongue	(1)	(0)	(0)	(0)
CARDIOVASCULAR SYSTEM				
Blood Vessel	(1)	(1)	(3)	(2)
Aorta, Inflammation, Chronic Active				1 (50%)
Heart	(50)	(49)	(50)	(50)
Cardiomyopathy	1 (2%)		1 (2%)	
Mineralization		1 (2%)		
Thrombosis			1 (2%)	
Artery, Inflammation, Chronic Active		3 (6%)	2 (4%)	1 (2%)
Valve, Inflammation, Suppurative	1 (2%)			
ENDOCRINE SYSTEM				
Adrenal Cortex	(50)	(49)	(50)	(49)
Accessory Adrenal Cortical Nodule		2 (4%)	1 (2%)	

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Hematopoietic Cell Proliferation			1 (2%)	
Mineralization			1 (2%)	
Subcapsular, Hyperplasia	48 (96%)	49 (100%)	50 (100%)	49 (100%)
Zona Fasciculata, Hyperplasia		1 (2%)	2 (4%)	1 (2%)
Adrenal Medulla	(50)	(49)	(50)	(49)
Hyperplasia			1 (2%)	
Islets, Pancreatic	(50)	(49)	(50)	(50)
Hyperplasia	2 (4%)			
Parathyroid Gland	(43)	(41)	(33)	(36)
Cyst	2 (5%)			
Pituitary Gland	(49)	(49)	(47)	(44)
Pars Distalis, Angiectasis	1 (2%)			1 (2%)
Pars Distalis, Cyst		2 (4%)		
Pars Distalis, Hyperplasia	7 (14%)	11 (22%)	4 (9%)	
Thyroid Gland	(48)	(49)	(49)	(47)
Ectopic Thymus		1 (2%)	1 (2%)	
Inflammation, Chronic Active	4 (8%)	7 (14%)	5 (10%)	2 (4%)
Ultimobranchial Cyst			1 (2%)	
Follicle, Cyst	2 (4%)	2 (4%)		1 (2%)
Follicle, Degeneration	10 (21%)	14 (29%)	15 (31%)	4 (9%)
Follicular Cell, Hyperplasia	10 (21%)	12 (24%)	11 (22%)	3 (6%)

#### GENERAL BODY SYSTEM

None

#### GENITAL SYSTEM

Clitoral Gland	(50)	(49)	(49)	(47)
Inflammation, Chronic Active			1 (2%)	
Ovary	(50)	(48)	(49)	(48)
Atrophy	12 (24%)	5 (10%)	14 (29%)	20 (42%)
Cyst	9 (18%)	14 (29%)	19 (39%)	11 (23%)
Hyperplasia, Adenomatous			1 (2%)	
Mineralization	2 (4%)	1 (2%)		1 (2%)
Pigmentation	5 (10%)	3 (6%)		2 (4%)
Bilateral, Cyst	2 (4%)	1 (2%)		
Oviduct	(2)	(1)	(2)	(0)
Infiltration Cellular, Mononuclear Cell	1 (50%)			
Uterus	(50)	(49)	(50)	(50)

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Angiectasis				1 (2%)
Hemorrhage			1 (2%)	
Inflammation, Chronic Active			1 (2%)	
Thrombosis				1 (2%)
Endometrium, Hyperplasia, Cystic	40 (80%)	43 (88%)	42 (84%)	32 (64%)
Lymphatic, Angiectasis		1 (2%)		
HEMATOPOIETIC SYSTEM				
Bone Marrow	(49)	(49)	(50)	(50)
Lymph Node	(10)	(7)	(3)	(3)
Mediastinal, Hyperplasia, Lymphoid	6 (60%)	1 (14%)		1 (33%)
Renal, Hematopoietic Cell Proliferation	1 (10%)			
Lymph Node, Mandibular	(49)	(49)	(46)	(43)
Hyperplasia, Lymphoid	3 (6%)	9 (18%)	2 (4%)	2 (5%)
Infiltration Cellular, Mast Cell			1 (2%)	
Pigmentation	1 (2%)			
Lymph Node, Mesenteric	(49)	(48)	(49)	(49)
Hemorrhage			1 (2%)	
Hyperplasia, Lymphoid	6 (12%)	1 (2%)		
Inflammation, Chronic Active	1 (2%)			
Artery, Inflammation, Chronic Active		1 (2%)		
Spleen	(49)	(49)	(50)	(50)
Hematopoietic Cell Proliferation	9 (18%)	6 (12%)	5 (10%)	3 (6%)
Lymphoid Follicle, Hyperplasia	8 (16%)		1 (2%)	2 (4%)
Thymus	(47)	(49)	(50)	(47)
Atrophy	8 (17%)	3 (6%)	5 (10%)	2 (4%)
Cyst	32 (68%)	29 (59%)	25 (50%)	14 (30%)
Ectopic Parathyroid Gland	9 (19%)	10 (20%)	8 (16%)	2 (4%)
Hyperplasia, Lymphoid		1 (2%)	3 (6%)	
INTEGUMENTARY SYSTEM				
Mammary Gland	(50)	(49)	(50)	(46)
Hyperplasia, Cystic			1 (2%)	
Skin	(50)	(49)	(50)	(50)
MUSCULOSKELETAL SYSTEM				
Bone	(49)	(49)	(50)	(50)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Fibrous Osteodystrophy	3 (6%)	3 (6%)	1 (2%)	4 (8%)
Skeletal Muscle	(4)	(2)	(1)	(2)
Infiltration Cellular, Lymphoid	1 (25%)			
Infiltration Cellular, Mononuclear Cell	1 (25%)			
Inflammation, Chronic Active	1 (25%)			1 (50%)
NERVOUS SYSTEM				
Brain	(50)	(49)	(50)	(50)
Compression		1 (2%)	2 (4%)	
Degeneration			1 (2%)	
Hemorrhage			1 (2%)	
Hydrocephalus	1 (2%)			
Artery, Inflammation, Chronic Active			1 (2%)	1 (2%)
Cerebrum, Neuron, Necrosis			1 (2%)	
Peripheral Nerve	(1)	(0)	(1)	(0)
Sciatic, Demyelination			1 (100%)	
Spinal Cord	(1)	(0)	(1)	(0)
Demyelination			1 (100%)	
RESPIRATORY SYSTEM				
Lung	(50)	(49)	(50)	(50)
Infiltration Cellular, Mononuclear Cell		1 (2%)		
Inflammation, Chronic Active	3 (6%)			
Mineralization	2 (4%)			
Alveolar Epithelium, Hyperplasia		5 (10%)		2 (4%)
Alveolus, Infiltration Cellular, Histocyte		3 (6%)		
Mediastinum, Infiltration Cellular, Mononuclear Cell	1 (2%)			
Nose	(49)	(49)	(50)	(50)
Inflammation, Chronic Active		1 (2%)	14 (28%)	41 (82%)
Glands, Dilatation	12 (24%)	36 (73%)	48 (96%)	47 (94%)
Glands, Hyperplasia		7 (14%)	42 (84%)	43 (86%)
Glands, Inflammation, Chronic Active	1 (2%)	6 (12%)	21 (42%)	38 (76%)
Nasolacrimal Duct, Inflammation, Suppurative			2 (4%)	3 (6%)
Olfactory Epithelium, Accumulation, Hyaline Droplet	1 (2%)	1 (2%)	27 (54%)	25 (50%)
Olfactory Epithelium, Degeneration	2 (4%)	1 (2%)	34 (68%)	24 (48%)

a - Number of animals examined microscopically at site and number of animals with lesion

TDMS No. 95011 - 06  
 Test Type: CHRONIC  
 Route: GAVAGE  
 Species/Strain: MICE/B6C3F1

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)  
 5-(HYDROXYMETHYL)-2-FURFURAL  
 CAS Number: 67-47-0  
 Pathologist: TOFT, J. - Blackshear, P.

Date Report Requested: 11/10/2006  
 Time Report Requested: 09:06:29  
 First Dose M/F: 08/09/01 / 08/08/01  
 Lab: BAT

B6C3F1 MICE FEMALE	0 MG/KG	188 MG/KG	375 MG/KG	750 MG/KG
Olfactory Epithelium, Hyperplasia			8 (16%)	24 (48%)
Olfactory Epithelium, Metaplasia	1 (2%)	5 (10%)	30 (60%)	40 (80%)
Respiratory Epithelium, Accumulation, Hyaline Droplet	4 (8%)	4 (8%)	36 (72%)	27 (54%)
SPECIAL SENSES SYSTEM				
Eye	(49)	(49)	(50)	(50)
Atrophy			2 (4%)	
Anterior Chamber, Inflammation, Suppurative	1 (2%)			
Cornea, Hyperplasia	1 (2%)			
Cornea, Inflammation, Chronic Active	1 (2%)		1 (2%)	1 (2%)
Lens, Cataract			1 (2%)	
Harderian Gland	(50)	(48)	(50)	(48)
Hyperplasia		2 (4%)	4 (8%)	2 (4%)
Inflammation, Chronic Active		1 (2%)		
URINARY SYSTEM				
Kidney	(50)	(49)	(50)	(50)
Atypia Cellular		1 (2%)		
Infarct		4 (8%)	1 (2%)	
Infiltration Cellular, Mononuclear Cell				1 (2%)
Metaplasia, Osseous	2 (4%)	2 (4%)	1 (2%)	
Mineralization	13 (26%)	3 (6%)	5 (10%)	2 (4%)
Nephropathy	32 (64%)	42 (86%)	33 (66%)	26 (52%)
Artery, Inflammation, Chronic Active		1 (2%)	1 (2%)	
Renal Tubule, Cyst				1 (2%)
Urinary Bladder	(50)	(49)	(49)	(50)
Infiltration Cellular, Mononuclear Cell				1 (2%)
Artery, Inflammation, Chronic Active			1 (2%)	

\*\*\* END OF REPORT \*\*\*